Clinical Trials Directory

Trials / Unknown

UnknownNCT03223142

Standardization of Multi-modal Tumor Ablation Therapy System

A Pilot Study of Multi-mode Precision Ablation System for the Treatment of Liver Malignant

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Shanghai Zhongshan Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study will document for the safety and efficacy of image guided multi-mode precision ablation system (the combination of cryoablation and radiofrequency ablation) for the treatment of liver malignant, as well as provide the indicator of antitumor immune response for liver malignant in China.

Detailed description

Either Cryoablation or Radiofrequency Ablation has been well accepted and widely used in clinical practice for solid tumor treatments with various commercial systems. Previous studies have established that locally exerting great thermal and mechanical stress through alternating freezing and heating abruptly broke the tumor cells and micro-vasculature in situ, enabling complete damage of primary tumor. Large amount of biological stimuli was released during this process to enhance body anti-tumor immunological response. This method thus may inhibit distal metastases and increase the survival rate. The investigators hypothesized that multi-mode thermal method (the combination of cryoablation, radiofrequency ablation) might trigger a whole body anti-tumor immune response for malignant tumor basing on multi-scale bio-thermal responses at molecular, cellular, tumor angiogenesis and tissue levels. The purpose of this study was to prospectively investigate the safety and feasibility of multi-mode precision ablation system for the treatment of liver malignant.

Conditions

Interventions

TypeNameDescription
DEVICEMulti-modal Precision AblationIn Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation

Timeline

Start date
2017-07-01
Primary completion
2019-12-01
Completion
2020-07-01
First posted
2017-07-21
Last updated
2017-07-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03223142. Inclusion in this directory is not an endorsement.